American Society of Hematology - 64th Annual Meeting and Exposition. New Orleans - December 10-13, 2022

Advanced Practice Providers (APPs) in Hematology: Work Practices, Interactions with Physicians, and Opportunities for Collaboration within the American Society of Hematology (ASH)

The Roadmap to Integrate Diversity, Equity, and Inclusion in Hematology Clinical Trials: An ASH Initiative Submitted on Behalf of the Entire Roadmap to Improve DEI in Clinical Trials Working Group

Building Capacity in Sub-Saharan Africa to Address Sickle Cell Disease: The Consortium on Newborn Screening in Africa (CONSA)

A Systematic Review of 72 ASH Plenary and Late Breaking Abstracts for Racial Representation: A Health Equity Call to Action

Decision theoretical foundations of clinical practice guidelines: an extension of the ASH thrombophilia guidelines

How Balanced Is Gender Representation at ASH? a Cross-Sectional Analysis

Predictive Tool to Support Decision-Making about Management of Conflicts of Interest for Guideline Development: Derivation and Validation

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J. Evan Sadler III MD PhD (9 November 1951 – 13 December 2018)

Duplicate Submissions to the American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) Meetings.

To update American Society of Clinical Oncology/American Society of Hematology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. An Update Committee reviewed data published between January 2007 and January 2010. MEDLINE and the Cochrane Library were searched. The literature search yielded one new individual patient data analysis and four literature-based meta-analyses, two systematic reviews, and 13 publications reporting new results from randomized controlled trials not included in prior or new reviews. For patients undergoing myelosuppressive chemotherapy who have a hemoglobin (Hb) level less than 10 g/dL, the Update Committee recommends that clinicians discuss potential harms (eg, thromboembolism, shorter survival) and benefits (eg, decreased transfusions) of ESAs and compare these with potential harms (eg, serious infections, immune-mediated adverse reactions) and benefits (eg, rapid Hb improvement) of RBC transfusions. Individual preferences for assumed risk should contribute to shared decisions on managing chemotherapy-induced anemia. The Committee cautions against ESA use under other circumstances. If used, ESAs should be administered at the lowest dose possible and should increase Hb to the lowest concentration possible to avoid transfusions. Available evidence does not identify Hb levels ≥ 10 g/dL either as thresholds for initiating treatment or as targets for ESA therapy. Starting doses and dose modifications after response or nonresponse should follow US Food and Drug Administration-approved labeling. ESAs should be discontinued after 6 to 8 weeks in nonresponders. ESAs should be avoided in patients with cancer not receiving concurrent chemotherapy, except for those with lower risk myelodysplastic syndromes. Caution should be exercised when using ESAs with chemotherapeutic agents in diseases associated with increased risk of thromboembolic complications. Table 1 lists detailed recommendations.

Publication Patterns of Cancer Cost-Effectiveness Studies Presented at the American Society of Hematology: Timeliness of Publication, Quality and Possible Bias.

Enhancing Diversity, Equity and Inclusion in Clinical Research: Strategies Used By Clinical Investigators

Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences

The ASH/ASCO clinical guidelines on the use of erythropoietin